TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00246350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 16 light massage treatments and hot packs
Study: NCT01509339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study: NCT03805386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician directed opioid prescribing
Description: Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient directed opioid prescribing
Description: Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
Study: NCT00246350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: 8 high velocity, low amplitude spinal manipulation treatments and hot pack

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: 16 high velocity, low amplitude spinal manipulation treatments and hot pack
Study: NCT02902224

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: 300ml tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g glucose via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 300ml tap water with 25g fructose via nasogastric tube
Study: NCT02658253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRIMVAC
Description: 3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Study: NCT03271580

Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Blood pressure test

Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Blood pressure test
Study: NCT05791123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket
Description: Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
Study: NCT00740129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg intravenous infusion once
Study: NCT04298307

Intervention type: OTHER
Intervention: Intracoronary lithotripsy (ICL)
Description: ICL using the Shockwave catheter.
Study: NCT02658253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRIMVAC
Description: 3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRIMVAC
Description: 3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRIMVAC
Description: 3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Study: NCT02303327

Intervention type: RADIATION
Group type: OTHER
Intervention: EBRT + HDR brachytherapy boost
Description: Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
Study: NCT02303327

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Dose Escalation Radiotherapy
Description: Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Androgen deprivation therapy
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Study: NCT02620566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain- Caudal
Description: Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- Local
Description: Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
Study: NCT00256724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance Threshold Device
Description: Active impedance threshold device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ITD
Description: sham impedance threshold device
Study: NCT00987311

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1- Dairy drink containing probiotics A
Description: 1- Dairy drink containing probiotics A

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2- Dairy drink containing probiotics B
Description: 2- Dairy drink containing probiotics B

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 3- Dairy drink without probiotics (control)
Description: 3- Dairy drink without probiotics (control)
Study: NCT00171171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study: NCT03222687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
Study: NCT00640965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-VPA
Description: DP-VPA dose escalation to 900mg, then continued for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DP-VPA Placebo
Description: Matching Placebo to Active, dose escalation, then continued for 8 weeks
Study: NCT04030572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: 0.1 mg tabs, one by mouth daily at bedtime for one week
Study: NCT04151433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).
Description: cf. different arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).
Description: cf. different arms
Study: NCT01009008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Activated Controlled Expansion Device
Description: Patient activated controlled expansion for post-mastectomy breast reconstruction
Study: NCT02898896

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: Additional 21 ml of blood will be collected
Study: NCT01944124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Prescription
Description: An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
Study: NCT00835250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal hybrid NOTES cholecystectomy
Description: Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Extirpation of the gallbladder by a surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Extirpation of the gallbladder by a surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Extirpation of the gallbladder by a surgical procedure
Study: NCT03409783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENSO Device
Description: An active ENSO device that delivers neuromodulation therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Device
Study: NCT03425617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO via Respimat® single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO via Respimat® single dose
Study: NCT02150655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02064907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Orally Disintegrating Tablets
Description: Dexlansoprazole delayed-release, orally disintegrating (OD) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Orally Disintegrating Tablets
Description: Dexlansoprazole delayed-release, orally disintegrating (OD) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Capsules
Description: Dexlansoprazole delayed-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Delayed Release Capsules
Description: Dexlansoprazole delayed-release capsules
Study: NCT01234545

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
Study: NCT00905255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study: NCT03039556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Daily Steps
Description: Complete normal daily ambulation for one week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-Reduction
Description: Reduce daily ambulation to fewer than 1000 steps per day for two weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to Normal Daily Steps
Description: Increase daily ambulation to 100% of normal daily step-count for two weeks
Study: NCT02506322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEKT - Cognitive-Behavioral-Emotional
Description: This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FEST - Clinical Supportive Educational
Description: This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
Study: NCT01795989

Intervention type: DEVICE
Intervention: 1.5T MRI Elbow Coil
Description: Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.

Intervention type: DEVICE
Intervention: 1.5T MRI Elbow Coil
Description: Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
Study: NCT03149484

Intervention type: DEVICE
Intervention: Personal remote microphone (RM) system
Description: Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.

Intervention type: OTHER
Intervention: Subjective Questionnaire
Description: These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
Study: NCT03357016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training programs
Description: High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training programs
Description: High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training programs
Description: High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
Study: NCT01110356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
Study: NCT03982381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Experimental treatment
Study: NCT04513015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant diet
Description: The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal dietetic scheme
Description: Isocaloric, normolipidic diet for age and sex
Study: NCT03265808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic human mesenchymal stem cells (allo-hMSCs)
Description: Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
Study: NCT03149484

Intervention type: OTHER
Intervention: Subjective Questionnaire
Description: These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
Study: NCT04178876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ethanol sclerotherapy
Description: Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping technique
Description: Endometrioma laparoscopic cystectomy
Study: NCT03140709

Intervention type: DRUG
Intervention: Oxytocin
Description: Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr

Intervention type: DRUG
Intervention: Oxytocin
Description: Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr
Study: NCT02350868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT0E028
Description: The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
Study: NCT02370173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTSD wavelength-1 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PTSD wavelength-2 bright light
Description: 6 weeks daily light exposure, 30 minutes per morning.
Study: NCT02695316

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group Discussion in native Language
Description: Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group Discussion
Description: Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription

Intervention type: OTHER
Group type: OTHER
Intervention: One-to-one Interview
Description: One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective Quantitative Analysis
Description: Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
Study: NCT00966706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given systemically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given systemically
Study: NCT02553993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii Fit(30 Mins)
Description: Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback(30 Mins)
Description: Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
Study: NCT00966706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given systemically
Study: NCT02553993

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional weight-shifting(30 Mins)
Description: Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
Study: NCT03378921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
Study: NCT02679300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise group
Study: NCT01110356

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.